Eddie J. Sullivan, PhD, is the President of SAB Biotherapeutics, Inc., where he has been influential since the company's inception in 2014. With a robust background in biotechnology, he has held leadership roles in various biopharma companies for over 25...

Eddie J. Sullivan, PhD, is the President of SAB Biotherapeutics, Inc., where he has been influential since the company's inception in 2014. With a robust background in biotechnology, he has held leadership roles in various biopharma companies for over 25 years. Dr. Sullivan is known for his expertise in developing immunotherapies for infectious diseases, cancer, and autoimmune disorders. He has successfully raised over $250 million for biopharmaceutical platforms and led many mergers and acquisitions. Previously, he served as CEO of Hematech, a subsidiary of Kyowa Hakko Kirin. His significant contributions to the biotechnology field are also seen in his roles on various boards, including the Biotechnology Innovation Organization (BIO). Notably, he has been instrumental in shaping policies around animal biotechnology and global health. He also brings academic acumen with a doctorate in a relevant field and an education from top universities like the University of Arizona and Brigham Young University. Dr. Sullivan's varied experiences make him a key player in the realm of biotechnology, focusing on impactful solutions for health problems.